Ladenburg Thalmann Financial Services Begins Coverage on Eyenovia (EYEN)

Research analysts at Ladenburg Thalmann Financial Services assumed coverage on shares of Eyenovia (NASDAQ:EYEN) in a research report issued on Tuesday, February 20th, Marketbeat reports. The brokerage set a “buy” rating and a $35.00 price target on the stock. Ladenburg Thalmann Financial Services’ target price indicates a potential upside of 296.38% from the stock’s previous close.

Separately, Roth Capital began coverage on shares of Eyenovia in a research note on Tuesday, February 20th. They set a “buy” rating and a $20.00 price target on the stock.

Shares of Eyenovia (NASDAQ:EYEN) traded down $0.18 during trading on Tuesday, hitting $8.83. 12,924 shares of the stock were exchanged, compared to its average volume of 28,921. Eyenovia has a twelve month low of $7.32 and a twelve month high of $10.74.

In related news, Director Fredric N. Eshelman bought 335,000 shares of the stock in a transaction on Monday, January 29th. The shares were bought at an average cost of $10.00 per share, for a total transaction of $3,350,000.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

COPYRIGHT VIOLATION NOTICE: This report was published by StockNewsTimes and is the sole property of of StockNewsTimes. If you are accessing this report on another domain, it was stolen and reposted in violation of U.S. and international copyright and trademark laws. The correct version of this report can be accessed at

Eyenovia Company Profile

Eyenovia, Inc is a clinical stage biopharmaceutical company. The Company is engaged in developing a pipeline of ophthalmology products utilizing its piezo-print technology to deliver micro-doses of active pharmaceutical ingredients (micro-therapeutics) to the eye. Its product candidates include MicroProst, MicroStat, MicroTears and MicroPine.

Receive News & Ratings for Eyenovia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eyenovia and related companies with's FREE daily email newsletter.

Leave a Reply